Massive Bio, Inc. Partners with TheSocialMedwork to Help Cancer Patients Find Clinical Trials, Improve Health Outcomes, and Accelerate Adoption of Artificial Intelligence and Digital Health Solutions in Oncology | Business

0


NEW YORK – (BUSINESS WIRE) – Sep 28, 2021–

Massive Bio today announced that it has partnered with TheSocialMedwork to increase participation in clinical trials and the search for concrete evidence for cancer patients. This collaboration will strengthen Massive Bio’s ability to reach more cancer patients globally in need of clinical trials, and provide TheSocialMedwork with new ways to help its members fight cancer, at no cost and at scale using the SYNERGY-AI clinical trial pairing from Massive Bio. Solution. “This partnership between Massive Bio and TheSocialMedwork provides patients with a first-rate search and navigation tool to effectively guide thousands of patients to new treatments and clinical trials, with the click of a button on their computer or mobile phone,” said Selin Kurnaz, co-founder and CEO of Massive Bio.

Massive bio ( https://massivebio.com ) is known in the healthcare industry for its SYNERGY-Artificial Intelligence (AI) clinical trial matching solution, as well as its Virtual Tumor Board. Massive Bio is a leader in recruiting patient-centered clinical trials through AI whose mission is to provide cancer patients with access to clinical trials regardless of their location or financial situation. “We are very happy with our partnership with TheSocialMedwork,” said Selin Kurnaz.

TheSocialMedwork ( https://thesocialmedwork.com ) is a leading search engine and access platform for the latest medicines and was founded by experienced social health innovator Sjaak Vink, among others with the goal of helping all patients around the world have equal and equitable access to the latest and greatest health innovations. Over a million patients used TheSocialMedwork’s search engine last year. “Teaming up with Massive Bio to provide cancer patients with better access to clinical trials is an exciting development for both of our companies. Our partnership brings together an unprecedented research and access platform to connect cancer patients with the treatments that are right for them, regardless of their location, ”said Sjaak Vink, CEO of TheSocialMedwork.

About Massive Bio

Massive bios ( https://massivebio.com )’s mission is to provide access to clinical trials to each cancer patient, regardless of location and / or financial capacity. Massive Bio’s AI-powered platform connects cancer patients and their oncologists to biopharmaceutical clinical trials, dramatically improving access and match rates, helping to accelerate referrals. drug development timelines and create a new oncology data ecosystem for improved protocol design and real-world knowledge. Massive Bio controls the patient recruitment value chain starting with patient identification, followed by off-site AI-based virtual screening and resolution of any registration or recruitment issues. for recruiting clinical trials. While improving the lives of cancer patients, Massive Bio serves nearly two dozen pharmaceutical companies, contract research organizations (CROs) and suppliers. Oncology patient recruitment, site selection, real-world data services and AI-based scale trial screening services are provided to its corporate clients. Massive Bio was founded in 2015, is headquartered in New York City, and is privately funded by strategic and financial investors. For more information, visit the Massive Bio website or contact [email protected]

Massive Bio has also been awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI) to develop and characterize its Federal In-Depth Clinical Trials Matching System (DLCTMS) under the SBIR contract. No. 75N91020C00016.

About TheSocialMedwork

TheSocialMedwork ( https://thesocialmedwork.com ) is a social impact company that believes in health, freedom and opportunity. TheSocialMedwork helps people around the world find and access the latest medicines not available in their country as an independent medicine search engine and intermediary access platform. To date, patients in more than 90 countries have benefited from access to thousands of innovative life-improving medicines.

TheSocialMedwork believes that individuals have the right to freedom of access in health matters and is committed to empowering patients and physicians to make informed treatment decisions that are not limited by who you are or where you live. . With every patient that TheSocialMedwork serves, a flag illuminates the access gaps for regulators, manufacturers and healthcare systems so they can contribute, improve their own processes, and serve all who need it more effectively. TheSocialMedwork, headquartered in Amsterdam, was founded in 2015 and is funded by impact investors, including Esther Dyson and Jamie Heywood.

For more information, visit TheSocialMedwork website or contact [email protected]

View source version on businesswire.com:https://www.businesswire.com/news/home/20210928005205/en/

CONTACT: Selin Kurnaz, PhD

Co-founder and CEO of Massive Bio

[email protected]

Sjaak Vink

CEO of TheSocialMedwork

[email protected]

646-381-0675

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY HEALTH SMALL PHARMACEUTICAL COMPANY PROFESSIONAL SERVICES ONCOLOGY OTHER TECHNOLOGIES RESEARCH SOFTWARE GENERAL HEALTH SCIENCE DATA MANAGEMENT CLINICAL TRIALS

SOURCE: Massive Bio, Inc.

Copyright Business Wire 2021.

PUB: 09/28/2021 08: 00 / DISC: 09/28/2021 08:02

http://www.businesswire.com/news/home/20210928005205/en

Copyright Business Wire 2021.


Share.

About Author

Comments are closed.